期刊
ARCHIVES OF PHARMACAL RESEARCH
卷 41, 期 1, 页码 1-13出版社
PHARMACEUTICAL SOC KOREA
DOI: 10.1007/s12272-017-0979-x
关键词
Curcumin; 5-Fluorouracil (5-FU); Multidrug resistance (MDR); Cytotoxicity; Anticancer efficacy; Combination therapy
资金
- National Natural Science Foundation of China [81341124, 81101678]
- Science and Technology Support Project of Sichuan Province [2017JQ0013]
- Sichuan Provincial Human Resource and Social Security Department [2016-183]
- Joint Fund of Sichuan Province, Luzhou City and Southwest Medical University [14JC0134, 14ZC0026, 14ZC0066]
- Joint Fund of Luzhou City and Southwest Medical University [2015LZCYD-S09 (4/8)]
- Southwest Medical University
5-Fluorouracil (5-FU) alone or in combination with other therapeutic drugs has been widely used for clinical treatment of various cancers. However, 5-FU-based chemotherapy has limited anticancer efficacy in clinic due to multidrug resistance and dose-limiting cytotoxicity. Some molecules and genes in cancer cells, such as nuclear factor kappa B, insulin-like growth factor-1 receptor, epidermal growth factor receptor, cyclooxygenase-2, signal transducer and activator of transcription 3, phosphatase and tensin homolog deleted on chromosome ten and Bcl-2 etc. are related to the chemoresistance and sensitivity of cancer cells to 5-FU. The activation of these molecules and genes expressions in cancer cells will be increased or decreased with long-term exposure of 5-FU. Curcumin has been found to be able to negatively regulate these processes. In order to overcome the problems of 5-FU, curcumin has been used to combine with 5-FU in cancer therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据